Cargando…

Persons from racial and ethnic minority groups receiving medication for opioid use disorder experienced increased difficulty accessing harm reduction services during COVID-19

INTRODUCTION: The COVID-19 pandemic collided with the opioid epidemic and longstanding health inequities to exacerbate the disproportionate harms experienced by persons with opioid use disorder (OUD) who self-identify as from racial and ethnic minority groups. Disrupted access to harm reduction serv...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosales, Robert, Janssen, Tim, Yermash, Julia, Yap, Kimberly R., Ball, Elizabeth L., Hartzler, Bryan, Garner, Bryan R., Becker, Sara J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566093/
https://www.ncbi.nlm.nih.gov/pubmed/34742607
http://dx.doi.org/10.1016/j.jsat.2021.108648
_version_ 1784593941715222528
author Rosales, Robert
Janssen, Tim
Yermash, Julia
Yap, Kimberly R.
Ball, Elizabeth L.
Hartzler, Bryan
Garner, Bryan R.
Becker, Sara J.
author_facet Rosales, Robert
Janssen, Tim
Yermash, Julia
Yap, Kimberly R.
Ball, Elizabeth L.
Hartzler, Bryan
Garner, Bryan R.
Becker, Sara J.
author_sort Rosales, Robert
collection PubMed
description INTRODUCTION: The COVID-19 pandemic collided with the opioid epidemic and longstanding health inequities to exacerbate the disproportionate harms experienced by persons with opioid use disorder (OUD) who self-identify as from racial and ethnic minority groups. Disrupted access to harm reduction services (e.g., naloxone, sterile syringes, recovery support) is one pathway whereby COVID-19 might exacerbate health disparities. We tested the hypothesis that persons receiving medication for opioid use disorder (MOUD) who self-identify as from racial/ethnic minority groups would experience more disruptions in access to harm reduction services than persons identifying as non-Hispanic White, even when controlling for severity of opioid use and sociodemographics (e.g., education, income, biological sex, age). METHODS: Analyses used data from a cluster randomized trial that had enrolled 188 patients, all of whom had provided baseline data on sociodemographics and severity of opioid use, across eight opioid treatment programs. Data collectors re-contacted participants between May and June 2020 and 133 (71% response rate) agreed to complete a survey about access to harm reduction services. RESULTS: Twenty-six respondents (20%) identified as from racial/ethnic minority groups (predominantly Black, Hispanic, and/or biracial). Between 7% and 27% of respondents reported disrupted access to harm reduction services. Logistic regressions indicated that persons identifying as from racial/ethnic minority groups were 8–10 times more likely than persons identifying as non-Hispanic White to report reduced access to naloxone and sterile syringes (p < .01), even when accounting for potential confounding variables. CONCLUSIONS: This report concludes with a discussion of potential outreach strategies and policies to advance more equitable access to essential harm reduction services.
format Online
Article
Text
id pubmed-8566093
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-85660932021-11-04 Persons from racial and ethnic minority groups receiving medication for opioid use disorder experienced increased difficulty accessing harm reduction services during COVID-19 Rosales, Robert Janssen, Tim Yermash, Julia Yap, Kimberly R. Ball, Elizabeth L. Hartzler, Bryan Garner, Bryan R. Becker, Sara J. J Subst Abuse Treat Article INTRODUCTION: The COVID-19 pandemic collided with the opioid epidemic and longstanding health inequities to exacerbate the disproportionate harms experienced by persons with opioid use disorder (OUD) who self-identify as from racial and ethnic minority groups. Disrupted access to harm reduction services (e.g., naloxone, sterile syringes, recovery support) is one pathway whereby COVID-19 might exacerbate health disparities. We tested the hypothesis that persons receiving medication for opioid use disorder (MOUD) who self-identify as from racial/ethnic minority groups would experience more disruptions in access to harm reduction services than persons identifying as non-Hispanic White, even when controlling for severity of opioid use and sociodemographics (e.g., education, income, biological sex, age). METHODS: Analyses used data from a cluster randomized trial that had enrolled 188 patients, all of whom had provided baseline data on sociodemographics and severity of opioid use, across eight opioid treatment programs. Data collectors re-contacted participants between May and June 2020 and 133 (71% response rate) agreed to complete a survey about access to harm reduction services. RESULTS: Twenty-six respondents (20%) identified as from racial/ethnic minority groups (predominantly Black, Hispanic, and/or biracial). Between 7% and 27% of respondents reported disrupted access to harm reduction services. Logistic regressions indicated that persons identifying as from racial/ethnic minority groups were 8–10 times more likely than persons identifying as non-Hispanic White to report reduced access to naloxone and sterile syringes (p < .01), even when accounting for potential confounding variables. CONCLUSIONS: This report concludes with a discussion of potential outreach strategies and policies to advance more equitable access to essential harm reduction services. Elsevier Inc. 2022-01 2021-10-30 /pmc/articles/PMC8566093/ /pubmed/34742607 http://dx.doi.org/10.1016/j.jsat.2021.108648 Text en © 2021 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Rosales, Robert
Janssen, Tim
Yermash, Julia
Yap, Kimberly R.
Ball, Elizabeth L.
Hartzler, Bryan
Garner, Bryan R.
Becker, Sara J.
Persons from racial and ethnic minority groups receiving medication for opioid use disorder experienced increased difficulty accessing harm reduction services during COVID-19
title Persons from racial and ethnic minority groups receiving medication for opioid use disorder experienced increased difficulty accessing harm reduction services during COVID-19
title_full Persons from racial and ethnic minority groups receiving medication for opioid use disorder experienced increased difficulty accessing harm reduction services during COVID-19
title_fullStr Persons from racial and ethnic minority groups receiving medication for opioid use disorder experienced increased difficulty accessing harm reduction services during COVID-19
title_full_unstemmed Persons from racial and ethnic minority groups receiving medication for opioid use disorder experienced increased difficulty accessing harm reduction services during COVID-19
title_short Persons from racial and ethnic minority groups receiving medication for opioid use disorder experienced increased difficulty accessing harm reduction services during COVID-19
title_sort persons from racial and ethnic minority groups receiving medication for opioid use disorder experienced increased difficulty accessing harm reduction services during covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566093/
https://www.ncbi.nlm.nih.gov/pubmed/34742607
http://dx.doi.org/10.1016/j.jsat.2021.108648
work_keys_str_mv AT rosalesrobert personsfromracialandethnicminoritygroupsreceivingmedicationforopioidusedisorderexperiencedincreaseddifficultyaccessingharmreductionservicesduringcovid19
AT janssentim personsfromracialandethnicminoritygroupsreceivingmedicationforopioidusedisorderexperiencedincreaseddifficultyaccessingharmreductionservicesduringcovid19
AT yermashjulia personsfromracialandethnicminoritygroupsreceivingmedicationforopioidusedisorderexperiencedincreaseddifficultyaccessingharmreductionservicesduringcovid19
AT yapkimberlyr personsfromracialandethnicminoritygroupsreceivingmedicationforopioidusedisorderexperiencedincreaseddifficultyaccessingharmreductionservicesduringcovid19
AT ballelizabethl personsfromracialandethnicminoritygroupsreceivingmedicationforopioidusedisorderexperiencedincreaseddifficultyaccessingharmreductionservicesduringcovid19
AT hartzlerbryan personsfromracialandethnicminoritygroupsreceivingmedicationforopioidusedisorderexperiencedincreaseddifficultyaccessingharmreductionservicesduringcovid19
AT garnerbryanr personsfromracialandethnicminoritygroupsreceivingmedicationforopioidusedisorderexperiencedincreaseddifficultyaccessingharmreductionservicesduringcovid19
AT beckersaraj personsfromracialandethnicminoritygroupsreceivingmedicationforopioidusedisorderexperiencedincreaseddifficultyaccessingharmreductionservicesduringcovid19